Wilson Sonsini Goodrich & Rosati advised Versant Ventures and OrbiMed on the transaction. Helicore Biopharma, a biopharmaceutical company focused on the discovery and development of first-in-class...
Helicore Biopharma’s $65 Million Series A Financing Round
Esperto Medical’s Oversubscribed Series A Financing Round
Wilson Sonsini Goodrich & Rosati advised Esperto on the transaction. Esperto Medical™ (Esperto), a healthtech start-up specializing in critical care and remote patient monitoring, announced the...
Cleveland Diagnostics’ $75 Million Financing
Wilson Sonsini Goodrich & Rosati represented Cleveland Diagnostics on the transaction. Cleveland Diagnostics, a clinical-stage biotechnology company developing next-generation diagnostic tests for the early detection of...
Hughes & Company’s Investment in Voluware
Wilson Sonsini Goodrich & Rosati represented Voluware on the deal. Voluware, an award-winning provider of solutions to speed and simplify prior authorizations, announced a capital investment...
Boehringer Ingelheim’s Acquisition of Trutino Biosciences
Wilson Sonsini Goodrich & Rosati advised Trutino Biosciences on the deal. Boehringer Ingelheim, a leading research-driven biopharmaceutical company, announced the signing of an option to acquire...
Infinitum Electric’s $80 Million Series D Funding
Vinson & Elkins advised Riverstone Holdings LLC on the deal while Wilson Sonsini represented Infinitum Electric. Riverstone Holdings LLC acted as lead investor in Infinitum Electric’s...
Simcha Therapeutics’ $40 Million Series B Financing
Wilson Sonsini Goodrich & Rosati advised SR One on the deal. Simcha Therapeutics, a biotechnology company developing cytokine-based cancer immunotherapies, announced the closing of a $40...
Attralus’ $116 Million Series B Financing
Wilson Sonsini Goodrich & Rosati advised Logos Capital on the deal while Sidley represented Attralus, Inc. Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines...